Kennedy Capital Management, Inc. Cardiff Oncology, Inc. Transaction History

Kennedy Capital Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$1.17 - $2.61 $197,615 - $440,834	-168,902 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $3,259 - $11,201	-1,545 Reduced 0.91%	168,902 $419,000
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $27,868 - $38,951	-5,380 Reduced 3.06%	170,447 $1.02 Million
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $447,398 - $676,901	-89,301 Reduced 33.68%	175,827 $1.17 Million
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $21,579 - $32,579	-3,245 Reduced 1.21%	265,128 $1.76 Million
Q1 2021 May 14, 2021	BUY	$9.1 - $19.57 $1.01 Million - $2.17 Million	110,838 Added 70.36%	268,373 $2.49 Million
Q4 2020 Feb 12, 2021	BUY	$12.02 - $24.71 $1.89 Million - $3.89 Million	157,535 New	157,535 $2.83 Million

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $110M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.